Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC
Tuğçe Telli(Essen University Hospital), Wolfgang P. Fendler(Essen University Hospital), Robert Seifert(University Hospital Münster), Leonor Lopes(University Hospital of Bern), Lale Umutlu(Essen University Hospital), Kim M. Pabst(Klinik und Poliklinik für Nuklearmedizin), Claudia Kesch(Essen University Hospital), Kuangyu Shi(University Hospital of Bern), Ken Herrmann(Essen University Hospital), Viktor Grünwald(Essen University Hospital), Madeleine J. Karpinski(Essen University Hospital), Boris Hadaschik(Essen University Hospital)
Cited by 9
Related Papers
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
|Clinical Cancer Research|2022|145
Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting
|European Journal of Nuclear Medicine and Molecular Imaging|2019|131
Growth Hormone and Sex Steroid Effects on Bone Metabolism and Bone Mineral Density in Healthy Aged Women and Men
|The Journals of Gerontology Series A|2002|91
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
|Journal of Nuclear Medicine|2022|68
Superior Tumor Detection for<sup>68</sup>Ga-FAPI-46 Versus<sup>18</sup>F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma
|Journal of Nuclear Medicine|2023|63